Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Novartis
Eli Lilly and Company
National Cancer Institute (NCI)
Montefiore Medical Center
Tango Therapeutics, Inc.
Hoosier Cancer Research Network
Actuate Therapeutics Inc.
NRG Oncology
NRG Oncology
NRG Oncology
Mayo Clinic
Institut Cancerologie de l'Ouest
Assistance Publique - Hôpitaux de Paris
Mayo Clinic
Brigham and Women's Hospital
RasCal Therapeutics, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Filamon LTD
University Hospital Heidelberg
M.D. Anderson Cancer Center
Thomas Jefferson University
Shanghai Chest Hospital
University of California, Davis
Essen Biotech
Memorial Sloan Kettering Cancer Center
Second Affiliated Hospital of Nanchang University
Eli Lilly and Company
Var2 Pharmaceuticals
Stanford University
Mayo Clinic
University of Washington
Black Diamond Therapeutics, Inc.
City of Hope Medical Center
Degron Therapeutics Co.
National Cancer Institute (NCI)
Sun Yat-sen University
Dana-Farber Cancer Institute
University of Kentucky
National Cancer Institute (NCI)
Virginia Commonwealth University
Maastricht Radiation Oncology
Latin American Cooperative Oncology Group
Sun Yat-sen University
LigaChem Biosciences, Inc.
Alpha Biopharma (Jiangsu) Co., Ltd.
Washington University School of Medicine
Incyte Corporation
Jonsson Comprehensive Cancer Center